Status:
UNKNOWN
Potential Role of n-3 Fatty Acids in the Treatment of NAFLD in Pediatric Patients
Lead Sponsor:
St. Justine's Hospital
Collaborating Sponsors:
Nutrisanté Canada
Conditions:
Non Alcoholic Fatty Liver Disease (NAFLD)
Eligibility:
MALE
8-18 years
Phase:
PHASE1
PHASE2
Brief Summary
Nonalcoholic hepatic steatosis (NASH) is defined as the amount greater than 5% of the total liver volume fat. Commonly known as NASH, it includes 4 stages histological ranging from the mere presence o...
Detailed Description
The aims of the investigators studies are to determine the plasma FA composition and to assess changes in the latter in response to n-3 supplementation in French-Canadian youth since (i) none of the a...
Eligibility Criteria
Inclusion
- boys (according to the literature review on NAFLD prevalence)
- body weight ≥ 95th percentile (based on the CDC Chart)
- aged \<18 years
- have a diffusely hyperechogenic liver at ultrasonography (consistent with NAFLD diagnostic)
- have normal or high transaminases (\> 2N).
Exclusion
- Subjects with pin or cochlear implants
- Subjects who consumed natural medicine products
- Those in whom a surgical procedure was planned
- the child who were found to consume fish, flaxseed oil and foods enriched with n-3 PUFA (eggs, or milk containing n-3 PUFA supplements), probiotics, vitamin E or use of drugs known to induce fatty liver during the study.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2015
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT02201160
Start Date
January 1 2009
End Date
December 1 2015
Last Update
July 25 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Ste-Justine
Montreal, Quebec, Canada, H3T 1C5